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ABSTRACT
Background: The persistence of the latent HIV-1 reservoir is a major obstacle to
curing HIV-1 infection. HIV-1 integrates into the cellular genome and some
targeted genomic loci are frequently detected in clonally expanded latently HIV-1
infected cells, for instance, the gene BTB domain and CNC homology 2 (BACH2).
Methods: We investigated HIV-1 promoter activity after integration into specific
sites in BACH2 in Jurkat T-cells. The HIV-1-based vector LTatCL[M] contains two
fluorophores: (1) Cerulean, which reports the activity of the HIV-1 promoter and
(2) mCherry driven by a constitutive promotor and flanked by genetic insulators.
This vector was inserted into introns 2 and 5 of BACH2 of Jurkat T-cells via CRISPR/
Cas9 technology in the same and convergent transcriptional orientation of BACH2,
and into the genomic safe harbour AAVS1. Single cell clones representing active
(Cerulean+/mCherry+) and inactive (Cerulean–/mCherry+) HIV-1 promoters were
characterised.
Results: Upon targeted integration of the 5.3 kb vector LTatCL[M] into BACH2, the
HIV-1 promoter was gradually silenced as reflected by the decrease in Cerulean
expression over a period of 162 days. Silenced HIV-1 promoters could be reactivated
by TNF-a and Romidepsin. This observation was independent of the targeted intron
and the transcriptional orientation. BACH2 mRNA and protein expression was
not impaired by mono-allelic integration of LTatCL[M].
Conclusion: Successful targeted integration of the HIV-1-based vector LTatCL[M]
allows longitudinal analyses of HIV-1 promoter activity.
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INTRODUCTION
Antiretroviral therapy (ART) efficiently blocks virus replication; however, it does not cure
HIV-1 infection due to the presence of replication-competent but silenced proviruses
preferentially integrated in long-lived resting CD4+ T-cells (Finzi et al., 1997; Wong et al.,
1997). Various factors and molecular mechanisms that result in HIV-1 latency have
been proposed (Ruelas & Greene, 2013). One such factor might be the integration site
of the provirus, which has been suggested to not only be responsible for silencing the
provirus, but also supporting cell expansion, thus maintaining the size of the HIV-1 latent
reservoir (Maldarelli et al., 2014; Wagner et al., 2014). Integration of HIV-1 into the
human genome is not random. In vivo and ex vivo HIV-1 integration site analyses
revealed that HIV-1 favours integration into introns of active transcription units in
gene-dense regions, although a minority of integration events outside of these regions have
consistently been observed (Ciuffi & Bushman, 2006; Kok et al., 2016; Mitchell et al.,
2004; Schroder et al., 2002; Stevens & Griffith, 1996). Furthermore, HIV-1 appears to target
active transcription units that are in close proximity to the nuclear pore (Marini et al.,
2015). On the population level, intragenic HIV-1 does not have a preference for either
transcriptional orientation of the targeted gene (Cohn et al., 2015; Schroder et al.,
2002; Stevens & Griffith, 1996). HIV-1-infected cells can undergo clonal expansion (Cesana
et al., 2017; Cohn et al., 2015;Maldarelli et al., 2014; Rezaei & Cameron, 2015; Satou et al.,
2017; Wagner et al., 2014), and the proviruses in these clonally expanded cells are often
located in specific regions of the human genome. One recurrent integration gene (RIG)
that has been observed across patients in numerous independent studies is the gene
BACH2, in which the provirus is almost exclusively found in intron 5 and in the same
transcriptional orientation as BACH2 (Cesana et al., 2017; Ikeda et al., 2007; Imamichi
et al., 2014; Mack et al., 2003; Maldarelli et al., 2014; Wagner et al., 2014). Since these
BACH2 integration sites were identified in HIV-1-infected individuals who have been on
ART for several years, it is conceivable that these proviruses are inactive, although it
remains unknown whether this presumed inactivity is a result of integration
site-dependent silencing of replication-competent proviruses or due to defective
proviruses.
To address the question of whether the HIV-1 promoter would be silenced upon
integration into intron 5 of BACH2 in the same transcriptional orientation, we employed
a modified version of our dual-fluorophore HIV-1-based vector, LTatC[M], which
reproduces features of active and latent HIV-1 infections (Kok et al., 2018). This vector
comprises two fluorescent reporter genes: (1) Cerulean, which reports the activity of the
HIV-1 promoter and (2) mCherry, the expression of which is driven by a constitutive
promoter and further protected from position-effect variegation by a pair of flanking
genetic insulators to identify cells harbouring an integrated vector (Uchida et al., 2013;
Villemure, Savard & Belmaaza, 2001; Yahata et al., 2007). In this study, we investigate
whether CRISPR/Cas9-mediated targeted HIV-1 integration in BACH2 is feasible and
would lead to inactivation of the HIV-1 promoter over time, and if so, whether it is locus
and/or transcriptional orientation dependent.
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MATERIALS AND METHODS
Generation of LTatCL[M] with target locus homologous arms and
Cas9/guide RNA-encoding plasmids
In the HIV-1 based, dual-fluorophore vector LTatC[M] the 3′LTR is located downstream
of the second fluorophore mCherry to enable retrovirus production and subsequent
infection of target cells (Kok et al., 2018). LTatC[M] was modified to LTatCL[M], that is,
the 3′LTR (L) was inserted between Cerulean (C) and the insulator cHS4 (Fig. 1A) to
further enhance the transcriptional independence of the HIV-1 promoter controlled
Cerulean. For targeted integration of this HIV-1 based, dual-fluorophore vector, retrovirus
production is not required. Thus, the HIV-1 3′LTR was relocated immediately
downstream of Cerulean. Additionally, a polyA signal was inserted between mCherry
([M]) and the second insulator sMAR8 (Fig. 1A). The homologous regions on both sides of
the targeted HIV-1 integration site in the human genome were obtained from NCBI
GenBank: BACH2 intron 5 (Accession No: NT_007299.13; 5′ arm nucleotides 93′502–94′
355, 3′ arm nucleotides 94′356–95′206), BACH2 intron 2 (5′ arm nucleotides 339′
363–340′186, 3′ arm nucleotides 340′187–341′034) and AAVS1 (Accession No: NC_
000019.10; 5′ arm nucleotides 1′399–2′218, 3′ arm nucleotides 2′219–3′051). Targeted
integration sites are depicted in Fig. 1B.
Primers to amplify the respective target locus homologous arms are listed in Table S1.
Each PCR reaction contained 100 ng of human genomic DNA (Sup-T1 cell line; obtained
through the NIH AIDS Reagent Programme, Division of AIDS, NIAID, NIH, from
Dr. Dharam Ablashi), 1x Platinum Taq PCR buffer (ThermoFisher, Waltham, MA, USA),
2 mM MgCl2 (ThermoFisher, Waltham, MA, USA), 0.2 mM dNTP (NEB), 0.4 mM of
each forward and reverse primer and 1 U Platinum Taq polymerase (ThermoFisher,
Waltham, MA, USA) in a total volume of 50 mL. The PCR cycling conditions were as
follows: 94 C for 2 min; 35 cycles of (94 C for 30 s, 55 C for 30 s, 68 C for 1 min); 68 C
for 5 min; 4 C hold.
The respective pair of target locus homologous arms were cloned into pGEM-T Easy
(Promega). Subsequently, the dual-fluorophore vector LTatCL[M] was cloned into each
plasmid in the same or convergent orientation via blunt-end cloning. The 6 plasmids
pBACH2_i5-, pBACH2_i2- and pAAVS1-LTatCL[M] were generated, containing the
homologous arms of the targeted HIV-1 integration loci in BACH2 intron 5, BACH2
intron 2, and in the genomic safe harbour AAVS1, respectively, containing LTatCL[M] in
both transcriptional orientations (s and c) (Fig. 1A).
Plasmids encoding Cas9 and guide RNAs were based on PX458 (Table S1). pSpCas9
(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid # 48138;
http://n2t.net/addgene:48138; RRID:Addgene_48138) (Ran et al., 2013). Annealing of
100 mM 5′ phosphorylated primers for the guide RNAs was performed using the following
conditions: 80 C for 5 min, 65 C for 7 min, 60 C for 7 min, 55 C for 7 min, 50 C
for 7 min, 45 C for 7 min, 40 C for 7 min, 35 C for 7 min, 30 C for 7 min, 25 C
for 7 min and 4 C hold. The annealed guide RNA primers were separately cloned into
PX458.
Inderbitzin et al. (2020), PeerJ, DOI 10.7717/peerj.10321 3/20
Figure 1 Targeted integration of the HIV-1 based, dual-fluorophore vector LTatCL[M] into specific
genomic loci in Jurkat T-cells. (A) Schematic diagram of the six HIV-1 based, dual-fluorophore vectors
LTatCL[M] (5′337 bp) flanked with the BACH2/AAVS1 homologous arms. LTatCL[M] contains two
fluorophores (Cerulean and mCherry) to distinguish between inactive and active HIV-1 promoters, that
is modelling latently and actively HIV-1 infected cells. The Cerulean cassette is under the control of the
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All plasmid sequences were confirmed by next-generation sequencing. Briefly, plasmids
were gel purified, diluted to 0.2 ng/ml, and 1 ng of the plasmids were processed using the
Illumina Nextera XT DNA library Prep kit. The DNA libraries were subsequently
paired-end or single-end sequenced with an Illumina MiSeq using the MiSeq Reagent Kit
v3 (150-cycle). Constructs are shown in Fig. 1A.
Transfection of Jurkat T-cells and single cell sorting
Prior to transfection, the six LTatCL[M] vectors (pBACH2_i5-, pBACH2_i5c-,
pBACH2_i2s-, pBACH2_i2c-, pAAVS1_s-, and pAAVS1_c- LTatCL[M]) were linearised
using 100 units of NsiI (NEB)/20 µg DNA. For transfection, 1 million Jurkat T-cells
were resuspended in 100 mL Nucleofector solution (Cell Line NucleofectorTM Kits,
Lonza) and combined with 2 mg of the linearised dual-fluorophore vector and 2 mg
of the corresponding gRNA/Cas9 plasmid: PX458_gBACH294,355–94,356 (intron 5),
PX458_gBACH2340,186–340,187 (intron 2) and PX458_gAAVS12,218–2,219 (AAVS1).
Nucleofection was performed using the programme X-001 for Jurkat T-cells (AmaxaTM
NucleofectorTM II, Lonza). Cells were cultured in RPMI-1640 medium media
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin
(10,000 units/ml penicillin, 10 mg/ml streptomycin).
At day 9 post transfection, cells were analysed using fluorescence-activated cell
sorting (FACS) and sorted at 20 cells per well in 96-well plates using a BD FACSAriaTM
III (BD Biosciences, Franklin Lakes, NJ, USA). Two cell phenotypes were sorted: 1.
Cerulean+/mCherry+ and 2. Cerulean−/mCherry+. This was done for each nucleofected
cell population: BACH2_i5s, BACH2_i5c, BACH2_i2s, BACH2_i2c, AAVS1_s, and
AAVS1_c. After 50 days, expanded cell cultures were analysed by flow cytometry and
subsequently single cell sorted. Longitudinal flow cytometric analysis of the cells were done
with the LSRFortessa II (BD Biosciences, Franklin Lakes, NJ, USA) and data were analysed
using the FlowJo Software v.10.0.8. (FLOWJO, LLC) (Fig. 1C).
Figure 1 (continued)
HIV-1 LTR whereas mCherry is under the control of an independent constitutive promoter (heIF4A1)
and flanked by two insulators (cHS4 and sMAR8). LTR, long terminal repeat; tat, HIV-1 transactivator;
IRES, internal ribosome entry site; cHS4, chicken hypersensitive site 4; tetO, tetracycline operator
sequences; heIF4A1, human eukaryotic initiation factor 4A1, gene promoter; sMAR8, synthetic matrix
attachment region 8. (B) Scheme of the targeted HIV-1 integration sites in BACH2 and AAVS1. Some
described HIV-1 integration sites in vivo are marked by red arrows (Maldarelli et al., 2014;Wagner et al.,
2014). (C) Percentage of Cerulean+/mCherry+ (white bars) and single mCherry+ (black bars) cells 9 days
post transduction of Jurkat T-cells targeting the different loci in BACH2 and AAVS1. The means and
standard deviations of 3 independent experiments are depicted. (D) Flow chart to generate monoclonal
cell lines. Jurkat T-cells were separately transfected with the vectors shown in A and the corresponding
gRNA/Cas9 plasmid. Nine days post transfection, the six different targeted HIV-1 integration variants
were each sorted by 20 cells per well for the phenotypes Cerulean+/mCherry+ and single mCherry+. Fifty
days post transfection, the cells were single cell sorted for each targeted integration variant for the two
phenotypes Cerulean+/mCherry+ and single mCherry+. After at least 25 days post second sorting, cells
were further characterised. (A–D). The in vivo observed preferential HIV-1 integration loci in BACH2,
BACH2_i5s, is highlighted by red boxes. Full-size DOI: 10.7717/peerj.10321/fig-1
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Activation of silenced HIV-1 promoter in cells with integrated
LTatCL[M] in BACH2
Over time silenced HIV-1 promoter in sorted Cerulean+/mCherry+ monoclonal cell lines
were reactivated using 10 ng/mL tumor necrosis factor alpha (TNF-a) and 4 nM
Romidepsin (Ro) (Selleckchem, Houston, TX, USA). After 24 hrs the cells were analysed
by flow cytometry.
Amplifying the junctions of LTatCL[M] integration into BACH2 and
AAVS1
Genomic DNA was extracted from 5 million transfected Jurkat T-cells using the
DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) and quantified by Quant-iTTM
PicoGreenTM dsDNA Assay kit (ThermoFisher Scientific, Waltham, MA, USA). To verify the
targeted integration of the dual-fluorophore vector LTatCL[M] into BACH2 or AAVS1,
the junctions of targeted integration were amplified by (semi-)nested PCR using 300 ng
genomic DNA containing 1x PCR buffer (Sigma–Aldrich, St. Louis, MI, USA), 1.5 mM
MgCl2 , 0.2 mM dNTPs, 0.5 mM of each respective forward and reverse primer
(Table S1), and 0.5 U JumpStart Taq DNA polymerase (Sigma–Aldrich, St. Louis,
MI, USA) in a total volume of 25 mL. The PCR cycling conditions were as follows: 94 C
for 2 min; 35–40 cycles of (94 C for 30 s, 63 C for 30 s, 72 C for 2 min); 72 C for 5 min;
4 C hold.
Mono-allelic or bi-allelic integration of LTatCL[M] into BACH2 and AAVS1 was
verified by PCR containing 100 ng genomic DNA, 1x PCR buffer, 1.5 mMMgCl2, 0.2 mM
dNTPs, 0.5 mM of each respective forward and reverse primers (Table S1), and 0.5 U
JumpStart Taq DNA polymerase in a total volume of 25 mL. The PCR cycling conditions
were as follows: 94 C for 2 min; 35 cycles (94 C for 30 s, 63 C for 30 s, 72 C for 2 min);
72 C for 5 min; 4 C hold.
Amplicons were sequenced by Sanger sequencing. The sequencing reaction contains 1x
Seqmix (Big Dy Termination v1.1, 1x Dilution Buffer (ThermoFisher, Waltham, MA,
USA)), and 100 ng DNA in a total volume of 40 mL. 0.2 mM primer was added (Table S1).
The PCR cycling condition were as follows: 40 cycles (96 C for 30 s, 50 C for 30 s,
60 C for 4 min); 4 C hold. Sequencing was performed following the manufacturer’s
instruction on an 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Near full-length amplification of integrated vector LTatCL[M]
Genomic DNA was extracted from 3 million transfected cells using the DNeasy Blood and
Tissue kit and quantified by Quant-iTTM PicoGreenTM dsDNA Assay kit. To investigate
the integrity of the integrated vector LTatCL[M], near full-length amplification of the
vector was performed, using genomic 300 ng DNA, 1x Long Amp Taq Reaction Buffer
(NEB), 0.4 mM dNTPs, 0.5 mM of each forward and reverse primer (Table S1) and
2.5 U Long Amp Taq Polymerase (NEB) in a total volume of 25 mL. The PCR cycling
conditions were as follows: 94 C for 30 min; 30 cycles of (94 C for 20 s, 58–61 C for 30 s,
72 C for 5 min); 72 C for 10 min; 4 C hold. A total of 1 ng purified amplicons were
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processed with the Nextera XT DNA Library Preparation Kit (Illumina) and subsequently
sequenced using the MiSeq reagent Kit v2 as described above.
Quantification of BACH2 mRNA expression
RNA was extracted from 3 million transfected cells using the All Prep DNA/RNA kit
(Qiagen, Hilden, Germany) and quantified by Nanodrop 1000. A total of 800 ng RNA was
reverse transcribed with Prime Script Reverse Transcriptase (Takara, Kyoto, Japan)
according to manufacturer’s instructions. To exclude contamination of plasmid and
genomic DNA contamination, reactions lacking reverse transcriptase were included
for each RNA sample. To quantify the mRNA level of BACH2, qPCR reactions were
performed in triplicates for each sample. cDNA was diluted 1:10 mixed with 1x PCR buffer
(Sigma–Aldrich, St. Louis, MI, USA), 1.5 mMMgCl2, 0.2 mM dNTP (NEB), 0.5 mM of each
Fw and Rv primers, 1x SYBR Green, 50 nM Rox, 0.5 U JumpStart Taq Polymerase
(Sigma–Aldrich, St. Louis, MI, USA) in a total volume of 25 mL. For each reaction, primer
pair was chosen to amplify a specific region of the BACH2 mRNA, spanning exon 7–8.
As a mRNA expression control glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH)
was amplified with GAPDH-specific primers (Table S1). The qPCR cycling conditions
were as follows: 94 C for 2 min; 40 cycles (94 C for 30 s, 55 C for 30 s, 63 C for 1 min
(collect data)); 72 C for 2 min; 95 C for 15 s; 4 C hold. Melt curves were collected
to analyse specificity of the amplification. The qPCR was performed in the ABI 7800
real-time PCR thermos-cycler then analysed using the 7500 Software v2.0.4, using the
comparative Ct method (Livak & Schmittgen, 2001).
Quantification of BACH2 protein expression
Cells were lysed using assay lysis buffer (50 mM Tris-HCL pH8, 150 mM NaCl, 0.5%
Na deoxycholate, 0.5% Triton X-100, 1x Protease inhibitor, ddH2O) and protein was
quantified using the Bicinchoninic acid assay (BCA) (PierceTM BCA Protein Assay Kit).
A total of 40 mg protein were mixed with loading dye and loaded on a BoltTM 4–12%
Bis–Tris Plus Gels (ThermoFisher Scientific, Waltham, MA, USA). Subsequently, proteins
were transferred onto a nitrocellulose membrane (iBlotTM 2 Transfer Stacks, ThermoFisher
Scientific, Waltham, MA, USA) blocked for 1 h at RT with 5% Top-Block wt/vol in
PBS supplemented with Tween-20 (10x PBS pH7.4, 0.1% Tween 20, and ddH2O).
For protein detection, the membrane was incubated with primary antibody (1/400 diluted
rabbit anti-BACH2 antibody (PA5-23642; ThermoFisher Scientific, Waltham, MA, USA)
and 1/5,000 diluted rabbit-anti-GAPDH antibody (ab9485, Abcam, Cambridge, UK))
overnight at 4 C. After washing the membrane four times with 1x PBS-T, the secondary
antibody, 1/10’000 diluted goat anti-rabbit IgG H&L (HRP) (ab97051; Abcam, Cambridge,
UK) was added and the membrane was incubated at RT for 1 h. The membrane was
then washed four times with 1x PB-T. To visualise the protein, Immobilon Crescendo
Western HRP substrate (Merck, Kenilworth, NJ, USA) was added to the membrane.
Chemiluminescence was captured with the Stella system (model 3200; Matlab Group
Companies, Natick, MA, USA).
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RESULTS
Targeted integration of the 5.3 kb HIV-1-based, dual-fluorophore vector
LTatCL[M] into BACH2 and AAVS1 via CRISPR/Cas9-mediated
homology directed repair
To investigate specific effects of HIV-1 integration into BACH2, four constructs were
generated containing the vector LTatCL[M] flanked by BACH2 homologous arms
(Fig. 1A) and integrated in Jurkat T-cells by means of the CRISPR/Cas9 technology.
The constructs were integrated into intron 5 of BACH2 in (1) the in vivo observed same (s)
and (2) the convergent (c) transcriptional orientation to investigate the potential impact of
transcriptional orientation on HIV-1 promoter activity. Furthermore, LTatCL[M] was
integrated into intron 2 of BACH2 in (3) the same and (4) the convergent transcriptional
orientation to investigate the position effect of HIV-1 integration into BACH2. Intron 2
was chosen as it has not yet been observed in HIV-1 infected patients, however, it was
frequently observed as HIV-1 integration locus in human CD34+ haematopoietic stem
cells infected in vitro with HIV-1(Maldarelli et al., 2014). In addition, LTatCL[M] was
integrated into intron 1 of PPP1R12C (protein phosphatase 1 regulatory subunit 12C) in
again both transcriptional orientations. This genomic locus was previously identified as
preferred site for integration of adeno-associated virus (AAV) DNA and designated
AAVS1 (AAV integration site) (Kotin, Linden & Berns, 1992). AAVS1 is widely used as
genomic safe harbour (GSH) althought not without some limitations particularly in the
context of future use in gene therapy trials (Papapetrou & Schambach, 2016; Sadelain,
Papapetrou & Bushman, 2011). Nevertheless, for research purposes it is considered a GSH
and we expect that the HIV-1 promoter will not be silenced when integrated in this GSH.
These six vector constructs and subsequently generated Jurkat T-cell clones were named
BACH2_i5s, BACH2_i5c, BACH2_i2s, BACH2_i2c, AAVS1_c, and AAVS1_s (Figs. 1A
and 1B).
Jurkat T-cells were nucleofected with linearised plasmids of the six LTatCL[M]
constructs. Nine days post transfection, the frequencies of stably transfected Cerulean+/
mCherry+ and single mCherry+ cells were between 0.1% and 1.8% (Fig. 1C). Cells were
sorted to enrich Cerulean+/mCherry+ (i.e., active HIV-1 promoter) and single mCherry+
(i.e., inactive HIV-1 promoter) cells (Fig. 1D).
To obtain monoclonal cell lines, a sequential flow cytometric sorting strategy was
employed. For all targeted integration variants, Cerulean+/mCherry+ and single mCherry+
cells were first sorted at 20 cells per well in 96-well plates and expanded in culture up
to 50 days post transfection. We analysed by means of flow cytometry a total of 92 cell
populations, and selected 29 for further expansion. These cells were single-cell sorted
to obtain monoclonal cell lines and expanded in culture for at least 25 days prior to further
characterisation. In total, 43 single cells expanded resulting in 43 monoclonal cell lines.
For each targeted integration variant (BACH2_i5s, BACH2_i5c, BACH2_i2s, BACH2_i2c,
AAVS1_s and AAVS1_c), at least one monoclonal cell line for each of the two phenotypes
(Cerulean+/mCherry+ and single mCherry+) were obtained with the exception of AAVS1_c,
single mCherry+ (Table 1). The monoclonal cell lines were characterised as follows.
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First, targeted integration of the HIV-1-based, dual-fluorophore vector LTatCL[M] was
verified by amplification of a fragment spanning the targeted gene up- or downstream of
the 5′ or 3′ homologous arms, respectively, and LTatCL[M]. Targeted integration was
confirmed in 39/43 monoclonal cell lines representing all three genomic loci in both
orientations and for both fluorescence phenotypes, except for AAVS1_c single mCherry+
(Table 1).
Second, targeted integration of LTatCL[M] in those 39 monoclonal cell lines was
verified to be mono-allelic by a PCR strategy that allows sufficient amplification only of
the not targeted BACH2 or AAVS1 allele by using primers up- and downstream of the
BACH2 or AAVS1 homologeous arms (Fig. 1A) and short PCR extension times.
All monoclonal cell lines contained a not targeted allele of the respective targeted
integration site (Table 1).
Third, BACH2 mRNA expression was quantified at 120 days post sorting in 11
Cerulean+/mCherry+ monolonal cell lines, representing each targeted integration variant.
A decrease of BACH2 mRNA expression could not be observed in any Cerulean+/
mCherry+ monolonal cell line (Fig. 2A; Table 1).
Forth, the potential impact on BACH2 protein expression after targeted integration of
LTatCL[M] into BACH2 was investigated by Western blot analyses at 120 days post
sorting. In line with unaltered BACH2 mRNA expression, BACH2 protein expression was
not impaired compared to non-transfected Jurkat T-cells in all 35 monoclonal cell lines
tested (Fig. 2B; Table 1).
Table 1 Characteristics of monoclonal Jurkat T-cell lines after targeted integration of LTatCL[M] into BACH2 and AAVS1. Cerulean+/
mCherry+ and single mCherry+ representing active and inactive HIV-1 promoters, respectively, in LTatCL[M] transfected cells. The in vivo




















BACH2_i5s Active 6 5/6 (83.3) 5/5 (100) 2/2 (100) 5/5 (100)
Inactive 7 5/7 (71.4) 5/5 (100) n.a. 4/4 (100)
BACH2_i5c Active 4 4/4 (100) 4/4 (100) 2/2 (100) 4/4 (100)
Inactive 1 1/1 (100) 1/1 (100) n.a. 1/1 (100)
BACH2_i2s Active 7 7/7 (100) 7/7 (100) 2/2 (100) 7/7 (100)
Inactive 4 3/4 (75) 3/3 (100) n.a. 3/3 (100)
BACH2_i2c Active 4 4/4 (100) 4/4 (100) 2/2 (100) 4/4 (100)
Inactive 2 2/2 (100) 2/2 (100) n.a. 2/2 (100)
AAVS1_s Active 2 2/2 (100) 2/2 (100) 1/1 (100) 2/2 (100)
Inactive 3 3/3 (100) 3/3 (100) n.a. n.a.
AAVS1_c Active 3 3/3 (100) 3/3 (100) 2/2 (100) 3/3 (100)
Inactive n.a. n.a. n.a. n.a. n.a.
Total 43 39/43 (90.7) 39/39 (100) 11/11 (100) 35/35 (100)
Notes:
1 Active= Cerulean+/mCherry+, inactive = single mCherry+
n.a. = not available
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Fifth, HIV-1 integration can affect various aspects of cellular physiology, for
instance, cell proliferation. To test whether targeted integration of LTatCL[M] into BACH2
would lead to an evolutionary advantage in cell growth, a cell-growth competition
assay was performed. The stably Cerulean and mCherry expressing BACH2_i5s_1.1
Cerulean+/mCherry+ and AAVS1_s_2.1 Cerulean+/mCherry+ monoclonal cell lines
were combined in an approximately 1:1 ratio with the parental Jurkat T-cell line and
cocultured for 25 days. A comparable decrease of Cerulean+/mCherry+ expression was
observed for both the BACH2_i5s_1.1 Cerulean+/mCherry+ and the AAVS1_s_2.1
Cerulean+/mCherry+ monoclonal cell line (Fig. S5).
In summary, we successfully performed targeted integration of the 5.3 kb HIV-1-based,
dual-fluorophore vector LTatCL[M] into various loci of the human genome via CRISPR/
Cas9-mediated homology-directed repair. We subsequently generated monoclonal cell
lines modelling actively and latently HIV-1-infected cells with integrated LTatCL[M] in
either transcriptional orientation in the targeted genomic loci.
Silencing of the HIV-1 promoter in Jurkat T-cells with integrated
LTatCL[M] in BACH2
To study the HIV-1 promoter activity over time in Cerulean+/mCherry+ monoclonal cell
lines, that is active HIV-1 promoter, the fluorescence profile was frequently monitored for
162 days. In the majority of Cerulean+/mCherry+ monoclonal cell lines with integrated
Figure 2 The mono-allelic integration of LTatCL[M] into BACH2 did not impair BACH2mRNA nor
BACH2 protein expression measured 120 days post sorting. (A) BACH2 mRNA expression was
quantified by amplification of a region in the mRNA downstream of BACH2_i5 and BACH2_i2. The bar
blot consists of two independent qPCR experiments, consisting of two replicates each. The qPCR was
carried out two times independently each in duplicates. The means and standard deviations are depicted.
One-way ANOVA was applied on all cell clone variants and showed no significance (p = 0.80).
(B) Western blot analysis of BACH2 protein expression, 110 kD BACH2 (upper panel) and 37 kD
GAPDH (lower panel) are shown for one exemplary experiment. The in vivo observed preferential HIV-1
integration loci in BACH2, BACH2_i5s, is highlighted by red boxes.
Full-size DOI: 10.7717/peerj.10321/fig-2
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LTatCL[M] in BACH2, the HIV-1 promoter was gradually silenced as observed by the
decline of the frequency of Cerulean+/mCherry+ cells to <50% in 16/18 monoclonal
cell lines within 24–162 days and to <10% in 10/18 monoclonal cell lines within
58–162 days (Fig. 3A; Fig. S1). This was observed independent of the BACH2 introns 2 or
5 chosen for targeted integration of LTatCL[M] and the transcriptional orientation of
LTatCL[M] relative to BACH2. In contrast, in all 5 AAVS1_s and AAVS1_c Cerulean+/
mCherry+ monoclonal cell lines the frequency of Cerulean+/mCherry+ cells remained
Figure 3 Longitudinal analysis of Cerulean+/mCherry+ monoclonal cell lines and reactivation of silenced HIV-1 promoter. (A) Longitudinal
frequency of Cerulean+/mCherry+ expression in 24 monoclonal cell lines for up to 162 days: 3x BACH2_i5s (depicted in red, first left panel), 4x
BACH2_i5c, 7x BACH2_i2s, 4x BACH2_i2c, 3x AAVS1_s, and 2x AAVS1_c. Each symbol represents one Cerulean+/mCherry+monoclonal cell line.
(B) Reactivation of silenced HIV-1 promoter upon treatment of monoclonal cell lines with 10 ng/mL TNF-a and 4 nM Romidepsin for 24 hrs
followed by FACS analysis. The experiment was carried out three times independently. The in vivo observed HIV-1 integration loci in BACH2,
BACH2_i5s, is highlighted by red boxes. Full-size DOI: 10.7717/peerj.10321/fig-3
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relatively stable for 162 days (>80% in 4/5 cell clones) as observed for one BACH2_i5s
clone (Fig. 3A). Overall, the HIV-1 promoter when integrated into the BACH2 gene is
silenced over time in the majority of Cerulean+/mCherry+ monoclonal cell lines whereas
it remains active when integrated into AAVS1.
Silenced HIV-1 promoters can be reactivated by TNF-a and
Romidepsin
To evaluate the reactivation of silenced HIV-1 promoters in Cerulean+/mCherry+
monoclonal cell lines, which gradually lost Cerulean expression, we performed an
activation assay using TNF-a and Romidepsin. TNF-a and Romidepsin in combination
have been shown to activate the silenced HIV-1 promoter (Kok et al., 2018; Sogaard et al.,
2015). These compounds were used to evaluate the reactivability of the silenced HIV-1
promoter in 8 Cerulean+/mCherry+ monoclonal cell lines with integrated LTatCL[M]
in BACH2. After 99 days, 1.6–48.2% of cells were Cerulean+/mCherry+. Upon treatment
with TNF-a and Romidepsin, the frequencies of Cerulean+/mCherry+ cells increased
to 61.6–89.8% (Fig. 3B), demonstrating that the silenced HIV-1 promoter was reactivatable
in those monoclonal cell lines.
Monoclonal single mCherry+ cell lines harbour large internal deletions
in LTatCL[M]
A total of 17 single mCherry+ monoclonal cell lines, presumably representing latently
HIV-1-infected cells, silenced at an early time point upon targeted HIV-1 integration, were
treated with TNF-a and Romidepsin to activate the HIV-1 promoter. Cerulean expression
was not induced by TNF-a and Romidepsin in any of these 17 monoclonal cell lines
(Fig. S1). To further investigate this, the whole vector LTatCL[M] was amplified and
sequenced in 8 of these 17 monoclonal cell lines. Surprisingly, the integrated vector
LTatCL[M] in these monoclonal single mCherry+ cell lines harboured large internal
deletions in the 5’HIV-1 LTR, tat and/or Cerulean cassette (Fig. 4). The monoclonal
BACH2_i5s cell lines 3.1 and 3.2, which were derived from the same cell culture after the
first sort, showed the same deletion in the IRES-Cerulean region (Fig. 4A). A similar
observation was made in the monoclonal BACH2_i2c cell lines 13.1 and 13.3, also
derived from the same first sorted cell population: The same deletion spanning from the
5′LTR to the Cerulean cassette was observed in both monoclonal cell lines (Fig. 4B).
All independent single mCherry+ monoclonal cell lines contained large deletions in
different regions of the vector suggesting that the plasmids were not the source of
those deletions. This was confirmed by next-generation sequencing of the plasmids not
showing any evidence for large deletions. Next, the integrated vector LTatCL[M] was
sequenced in a cell population of single mCherry+ cells immediately after the first sort,
9 days post transfection (Fig. S1). Evidence for numerous different large deletions were
observed in the 5’HIV-1 LTR, Tat, IRES and/or Cerulean (Fig. S1), indicating that those
deletions occurred early during targeted integration.
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DISCUSSION
We developed a novel model to study HIV-1 promoter activity based on CRISPR/
Cas9-mediated targeted integration of an 5’337 bp HIV-1-based, dual-fluorophore vector
into selected sites in the human genome. In our previous study, we have shown that
the HIV-1-based, dual-fluorophore vector LTatC[M] reproduces features of active and
latent HIV-1 infections (Kok et al., 2018). Here, we studied the fate of the HIV-1 promoter
in specific HIV-1 integration loci/sites by targeted integration of the vector LTatCL[M]
into BACH2 and AAVS1. In Jurkat T-cells, HIV-1-based vector integration into BACH2
led initially to an active HIV-1 promoter as shown by the expression of HIV-1 LTR
controlled Cerulean. Over time those monoclonal cell lines showed a gradual silencing of
the HIV-1 promoter. This might be due to transcriptional interference, which can
occur in two ways: Either through promotor occlusion or convergent transcription, in
which the transcription from the host genes interferes with HIV-1 transcription (Han
et al., 2008; Lenasi, Contreras & Peterlin, 2008; Shan et al., 2011). In our study, however,
HIV-1 integration into the two target loci of BACH2 intron 5 and intron 2 in both
orientations showed similar silencing of the HIV-1 promoter over time. Differences
were observed for the genomic safe harbour AAVS1, in which no substantial silencing of
the HIV-1 promoter was observed over a time period of 162 days. This raises the question,
whether BACH2 is an exceptional HIV-1 integration site promoting HIV-1 promoter
silencing or, vice versa, AAVS1 is an exceptional HIV-1 integration site preventing HIV-1
polyA
BACH2/AAVS1 sMAR8 mCherry heiF4A1 tetO cHS4 3’LTR 5’LTRIRES tatCerulean
polyA













Figure 4 Mapping of large deletions within LTatCL[M] in TNF-a/Romidepsin non-responsive,
single mCherry+ monoclonal cell lines. Deletions in the integrated vector LTatCL[M] are depicted
for monoclonal BACH2_i5, BACH2_i2 and AAVS1 monoclonal cell lines with integrated LTatCL[M] in
the same transcriptional orientation (A) and in the convergent transcriptional orientation (B). Black
horizontal bars show the amplified and sequenced regions of LTatCL[M] and large deletions are shown in
white horizontal bars. Light blue and light red vertical bars show the positions of the two fluorophores
Cerulean and mCherry, respectively. Vector schemes are depicted on top. The in vivo observed HIV-1
integration region site in BACH2, BACH2_i5s, is highlighted by red boxes. Different starting points of
amplicons were due to using different primer pairs for amplifications.
Full-size DOI: 10.7717/peerj.10321/fig-4
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promoter silencing. In a future study, we will be expanding the repertoire of investigated
HIV-1 integration sites.
In virally suppressed HIV-1-infected individuals, the provirus integrated into BACH2
has been found predominantly in intron 5 in the same transcriptional orientation as
the gene and has been linked with clonal expansion. However, in in vitro in HIV-1 infected
cell lines, integration has been found to occur randomly in the BACH2 gene, indicating
that the integration selection observed in vivo cannot be fully recapitulated (Maldarelli
et al., 2014; Wagner et al., 2014). The preference of HIV-1 integration into BACH2 intron
5 in the same orientation in vivo could be caused by: (1) Selection of BACH2 intron 5
integrants over other integrants over time (Hughes & Coffin, 2016), (2) BACH2 intron 5
is preferentially targeted by HIV-1 in primary CD4+ T-cells, presumably due to the spatial
location of this locus in the nucleus of target cells (Marini et al., 2015), or (3) distinct
alterations in BACH2 expression levels caused by different HIV-1 integration patterns.
BACH2 expression levels vary between T-cells in distinct differentiation stages (Richer,
Lang & Butler, 2016). An increase of BACH2 transcripts in regulatory and effector T-cells
were observed when HIV-1 was integrated in BACH2 (Cesana et al., 2017). Enhanced
expression of the wild-type BACH2 in regulatory T-cells leads to increased proliferation
capacity without affecting the cells’ phenotype (Cesana et al., 2017). Alteration of BACH2
expression might cause HIV-1 persistence in BACH2 intron 5 and expansion of the
cell. In Jurkat T-cells, as compared to primary CD4+ T-cells, the BACH2 expression levels
might be different (Shan et al., 2017). We measured BACH2 expression 120 days post
sorting. At this time point the majority of the transfected cell clones harboured silenced
HIV-1 promoters. We could not observe an inhibitory effect on BACH2mRNA or protein
expression when BACH2 introns 5 and 2 were targeted for integration with our HIV-1-
based vector. This indicates that other factors might lead to the persistence of HIV-1
in this locus in Jurkat T-cells. HIV-1 infection into a cellular gene can affect various aspects
of cellular physiology as for example proliferation or a longer half-life of the cell (Rezaei &
Cameron, 2015; Wagner et al., 2014). However, there was no evidence that targeted
integration of LTatCL[M] into BACH2 had an evolutionary advantage in cell growth in
competition with the parental Jurkat T-cell line.
The expression of Cerulean decreased over time in almost all BACH2 monoclonal cell
clones independent of the targeted intron and the orientation of HIV-1-based vector
integration. The slow decline and the presence of Cerulean positive cells for up to 162 days
in some of those monoclonal cell clones shows that targeted integration of LTatCL[M]
into BACH2 does not immediately and not completely lead to HIV-1 promoter silencing
in Jurkat T-cells. However, insulator-protected mCherry expression also declined in
some of those cell clones, suggesting a gradual and strong silencing effect at the BACH2
loci. This silencing was reversible as shown by the treatment of cell clones harbouring
silenced HIV-1 promoters with TNF-a and Romidepsin that led to HIV-1 promoter
reactivation. These observations are partly in line with Lange et al. (2018): They observed a
comparable reversible silencing of the HIV-1 promoter in BACH2 within 20–40 days
targeting two sites within BACH2 intron 5 via CRISPR/Cas9 and inserting one reporter
gene under the control of the HIV-1 LTR-promoter in the same transcriptional orientation
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as BACH2. Here, we observed the same phenotypes in another intron of BACH2 and
independent of the orientation of the HIV-1 integration. Furthermore, targeted integration
of LTatCL[M] into the genomic safe harbour AAVS1 did not lead to silencing of the
HIV-1 promoter. This model can be further expanded by insertion of, for instance, certain
HIV-1 genes, which will allow to study the impact of viral genes on the host’s expression
profile and cell cycle.
Mono-allelic integration of 5.3 kb long LTatCL[M] into BACH2 and AAVS1 has
been confirmed in monoclonal cell lines by amplifying and sequencing junctions of
integration. So far, the longest fragment inserted in human lymphocytes was 1.5 kb
long (Hung et al., 2018), hence, our findings show that insertion of a 3.5x larger fragment is
possible in Jurkat T-cells. Fragments of similar length (5.5 kb and 7.4 kb) have been
successfully integrated in other cell types (embryonic stem cells and zygotes) (Wang et al.,
2015).
Monoclonal cell lines expressing initially only mCherry, that is supposed to model
latently HIV-1 infected cells, were found to contain large deletions in the LTR-tat-
Cerulean cassette. Similar deletions were already observed by us when we used a variant
of our vector to generate retroviruses for infection of cells (Kok et al., 2018). There,
we speculated that the deletions were caused by error-prone HIV-1 reverse transcription
(Bebenek et al., 1989; Patel & Preston, 1994) or copy-choice recombination (Sanchez
et al., 1997; Simon-Loriere & Holmes, 2011), which is also observed in cells from HIV-1-
infected individuals (Ho et al., 2013). However, our current system does not require reverse
transcriptase prior to integration since we are using CRISPR/Cas9-mediated targeted
integration. Therefore, the deletions might be due to recombination events triggered by the
LTRs flanking the Cerulean cassette (Mager & Goodchild, 1989). Together with our
previous observation (Kok et al., 2018), our results underline the importance to further
investigate single fluorescent cell populations (representing latently HIV-1 infected cells)
in latency models using HIV-1-based vector systems. Beyond HIV-1, these findings might
also have implications for lentiviral vectors used for gene therapy.
CONCLUSION
Using the CRISPR/Cas9-technology, stable targeted integration of the 5.3 kb long
HIV-1 based, dual-fluorphore vector LTatCL[M] was successful, enabling longitudinal
studies on effects of selected genomic sites on HIV-1 promoter activity and cellular
phenotypes. Targeting the BACH2 gene revealed that loci within this gene are capable of
supporting an active HIV-1 promoter upon integration but its activity diminishes over
time in Jurkat T-cells. On the contrary, the HIV-1 promoter was not silenced when
integrated into the genomic safe harbour AAVSI of Jurkat T-cells.
LIST OF ABBREVIATIONS
ART Antiretroviral therapy
BACH2 BTB domain and CNC homology 2
AAVS1 Adeno-associated virus integration site 1
LTR Long terminal repeat
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LTatCL[M] 5′LTR—Tat-Cerulean-3′LTR-insulator-mCherry-insulator
TNF-a Tumor necrosis factor alpha
RIG Recurrent integration gene
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